Home » Stocks » CSBR

Champions Oncology, Inc. (CSBR)

Stock Price: $11.68 USD 0.22 (1.92%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $11.05 -0.63 (-5.39%) Feb 26, 6:02 PM
Market Cap 156.15M
Revenue (ttm) 37.42M
Net Income (ttm) -1.56M
Shares Out 13.06M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE 65.79
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $11.68
Previous Close $11.46
Change ($) 0.22
Change (%) 1.92%
Day's Open 11.61
Day's Range 11.25 - 11.96
Day's Volume 22,289
52-Week Range 4.02 - 13.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 1 month ago

HACKENSACK, NJ / ACCESSWIRE / January 19, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology company that is transforming drug discovery and development throug...

Accesswire - 1 month ago

HACKENSACK, NJ / ACCESSWIRE / January 5, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology company that is transforming drug discovery and development through...

Zacks Investment Research - 5 months ago

Champions Oncology (CSBR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Seeking Alpha - 5 months ago

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q1 2021 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of Champions Oncology (NASDAQ:CSBR) were unchanged in after-market trading after the company reported Q1 results.

Seeking Alpha - 7 months ago

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q4 2020 Results - Earnings Call Transcript

Benzinga - 7 months ago

Shares of Champions Oncology (NASDAQ:CSBR) rose 1.08% in after-market trading after the company reported Q4 results.

Seeking Alpha - 1 year ago

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Fiscal Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

In the long-run, does consistent market timing really matter to be a successful investor?

Other stocks mentioned: BSTC, CMD, RDNT, TRXC
GuruFocus - 1 year ago

Champions Oncology Inc (NASDAQ:CSBR) files its latest 10-K with SEC for the fiscal year ended on April 30, 2019.

Zacks Investment Research - 1 year ago

Champions Oncology, Inc. (CSBR) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Seeking Alpha - 1 year ago

Champions Oncology is a profitable, free cash flow positive contract research organization serving the immune-oncology and oncology market.

Seeking Alpha - 1 year ago

While the company reported a small (and unexpected) net loss in Q3 FY2019, it was a result of a one-time operational issue related to managing aggressive growth.

Seeking Alpha - 1 year ago

Champions Oncology, Inc (CSBR) CEO Ronnie Morris on Q3 2019 Results - Earnings Call Transcript

About CSBR

Champions Oncology develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and ... [Read more...]

Industry
Biotechnology
IPO Date
Mar 25, 1986
CEO
Dr. Ronnie Morris
Employees
143
Stock Exchange
NASDAQ
Ticker Symbol
CSBR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CSBR stock is "Strong Buy." The 12-month stock price forecast is 13.83, which is an increase of 18.41% from the latest price.

Price Target
$13.83
(18.41% upside)
Analyst Consensus: Strong Buy